1/31/2013 - Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
Read more

1/3/2013 - Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates
Read more

12/18/2012 - Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies
Read more

10/24/2012 - Sutro Biopharma Expands Senior Management Team
Read more

5/8/2012 - Sutro Closes $16.5 Million Second Tranche of Series C Financing
Read more

1/7/2012 - Sutro Announces Newly Formed Scientific Advisory Board - Renowned Researchers James A. Wells, Ph.D., and James R. Swartz, Sc.D., to Guide Sutro’s Advancing Therapeutic Pipeline
Read more

10/17/2011 - Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin.
Read more

5/19/2011 - Study Shows Sutro Biopharma’s Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals. Results Published in Biotechnology and Bioengineering Demonstrate that Cell-Free Production of a Biologically Active Human Cytokine Can be Scaled-up to Commercial Manufacturing Levels.
Read more Link to Article

1/7/2011 - Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel, Peptide-Based Therapeutics.
Read more

12/8/2010 - Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer. Appointment Reflects Biopharmaceutical Company's Commitment to the Development of Novel and Biosuperior Protein Therapeutics.
Read more

11/17/2010 -Sutro Biopharma Secures $36.5 Million in Series C Financing.
Read more

08/20/2009 - Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team.
Read more

06/09/2009 - Sutro Biopharma Adds to Extensive IP Portfolio with Two Newly Issued Patents and Two Patent Grant Notices. Covers the Only Cell-Free Synthesis Platform Applicable to Protein Discovery Through Production.
Read more

03/30/2009 - Sutro Biopharma Hits Major Technical Milestone, Reaching 100 Liter Scale for the Company’s Open Cell-free Protein Synthesis Technology. Milestone Triggers $15 Million Series B Financing.
Read more

01/12/2009 - William J. Newell Named Chief Executive Officer of Sutro Biopharma. Former CEO Daniel S. Gold, Ph.D. Becomes President and Chief Operating Officer. Company Notes Name Change from Fundamental Applied Biology and Relocation to South San Francisco.
Read more